ARTICLE | Clinical News
Lorvotuzumab mertansine regulatory update
August 23, 2010 7:00 AM UTC
ImmunoGen received Orphan Drug designation in the U.S. for lorvotuzumab mertansine to treat small cell lung cancer (SCLC). In addition, the COMP of the European Medicines Agency (EMA) issued a positiv...